2 May 2022
MYCELX Technologies Corporation
("MYCELX" or the "Company" (AIM: MYX)
Dealing by Director
The Company announces that it was notified on 2 May 2022 by Hal Alper, President, Chief Science Officer and a Director of the Company, that on 10 November 2021 he sold 22,500 Common Shares at a price of £0.70 per Common Share. Following this transaction, he continues to be interested in 1,219,546 Common Shares representing 5.31 per cent of the present issued capital of the Company and in 124,339 options over the Company's Common Shares.
For further information please contact:
MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO
|
Tel: +1 888 306 6843 |
Canaccord Genuity, Nominated Adviser Henry Fitzgerald-O'Connor Gordon Hamilton
|
Tel: + 44 20 7523 8000 |
Celicourt Mark Antelme Jimmy Lea |
Tel: +44 20 8434 2754 |
Notification of transactions of persons discharging managerial responsibility or connected persons
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Hal Alper
| ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Director | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| MYCELX Technologies Corporation | ||||
b)
| LEI
| 213800UJZINIK2VD1G48
| ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Common shares of US$0.025
USU624551078
| ||||
b)
| Nature of the transaction
| Disposal of Common Shares
| ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
|
n/a
n/a
| ||||
e)
| Date of the transaction
| 10/11/2021 | ||||
f)
| Place of the transaction
| London Stock Exchange |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.